[Pulmonary complications in patients with AIDS]

Area of Science:

• Infectious Diseases
• Immunology
• Pharmacology

Context:

• HIV infection, first reported in 1981, has seen significant prognosis improvement due to new drugs and treatment strategies.
• Highly Active Antiretroviral Therapy (HAART), introduced in Japan in 1997, dramatically reduced opportunistic infections and mortality.
• HAART is associated with side effects, including lipodystrophy syndrome (LDS), characterized by lipid redistribution and metabolic changes, increasing ischemic heart disease risk.

Purpose:

• To evaluate the effectiveness and side effects of HAART in HIV patients.
• To assess the prevalence of LDS in Japanese patients compared to Caucasian populations.
• To review treatment strategies for opportunistic infections, particularly Pneumocystis pneumonia (PCP), and manage drug intolerance.

Summary:

• HAART has significantly improved HIV patient survival but leads to side effects in 80% of patients, with 15% requiring treatment changes.
• Lipodystrophy syndrome (LDS), an emerging HAART side effect, involves lipid redistribution and metabolic alterations, posing cardiovascular risks.
• Pneumocystis pneumonia (PCP) remains a prevalent opportunistic infection, with sulfamethoxazole/trimethoprim (ST) as a primary treatment, though side effects limit its use.
• A desensitization protocol allows over 80% of patients intolerant to ST to successfully complete PCP treatment.

Impact:

• HAART has transformed HIV/AIDS management, improving quality of life and survival rates.
• Understanding and managing HAART-induced side effects like LDS is crucial for long-term patient health.
• Effective treatment and management of opportunistic infections like PCP are vital for preventing AIDS progression and mortality.
• Successful desensitization protocols enhance treatment adherence and outcomes for patients with drug intolerance.